Literature DB >> 2917127

A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma').

R Rimokh1, J P Magaud, F Berger, J Samarut, B Coiffier, D Germain, D Y Mason.   

Abstract

Two cases of non-Hodgkin's lymphoma are reported in which a chromosomal translocation was observed involving the same site (q35) on the long arm of chromosome 5. The other breakpoint involved in the translocation was chromosome 2 (p23) in one case and chromosome 3 (q12) in the other. Both cases were large cell lymphomas expressing CD30 antigen ('Ki-1 lymphoma'). One was clearly of T lymphoid origin, the other probably B cell derived. One other case of a Ki-1 lymphoma with 2;5 translocation (involving the same breakpoint on chromosome 5) has been reported previously, and it is suggested that this cytogenetic abnormality may be specifically associated with Ki-1 lymphoma. The literature contains a further eight cases of lymphoid neoplasms with a translocation involving a breakpoint at q35 on chromosome 5. They have all been described as cases of 'malignant histiocytosis', but the present findings make it likely that these cases were in reality also examples of Ki-1 lymphoma. The breakpoint at the q35 region on chromosome 5 is close to the position of the fms proto-oncogene, suggesting that an abnormality affecting this gene might possibly play a causal role in 'Ki-1 lymphoma'. However, DNA restriction fragment analysis of the present cases showed no evidence that the breakpoint on chromosome 5 involves the fms gene or its immediate vicinity.

Entities:  

Mesh:

Year:  1989        PMID: 2917127     DOI: 10.1111/j.1365-2141.1989.tb06270.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  30 in total

1.  5'-(RACE) identification of rare ALK fusion partner in anaplastic large cell lymphoma.

Authors:  N Scott Reading; Stephen D Jenson; Jeffrey K Smith; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

Review 2.  The molecular biology of B-cell lymphoma: clinicopathologic implications.

Authors:  P M Kluin; J H van Krieken
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

3.  High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma.

Authors:  R Rust; G Harms; T Blokzijl; M Boot; A Diepstra; J Kluiver; L Visser; S-C Peh; M Lim; W A Kamps; S Poppema; A van den Berg
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

Review 4.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

Review 5.  Non-Hodgkin Lymphoma in Children.

Authors:  John T Sandlund
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

6.  Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type.

Authors:  S A Pileri; K Pulford; S Mori; D Y Mason; E Sabattini; G Roncador; M Piccioli; C Ceccarelli; P P Piccaluga; D Santini; O Leone; H Stein; B Falini
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

Review 7.  Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review.

Authors:  Waseem Lone; Aisha Alkhiniji; Jayadev Manikkam Umakanthan; Javeed Iqbal
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

8.  High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma.

Authors:  E Cesarman; G Inghirami; A Chadburn; D M Knowles
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

9.  Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome.

Authors:  Sook Ryun Park; Ji Yeon Baek; Dong-Wan Kim; Seok-Ah Im; Tae-You Kim; Yung-Jue Bang; Noe Kyeong Kim; Yoon Kyung Jeon; Chul Woo Kim; Dae Seog Heo
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

Review 10.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.